IL17A and cancer: Via rising distal natural killer (NK) cells and inducing cancer‐specific CD8+ T cells with specific memories, lowering pro‐inflammatory cytokines including TNF and IL‐17, and through boosting the quantity of Th17 lymphocytes and FOXP3 in circulation within cancer mattresses.